Alli (orlistat 60 mg) is the only FDA-approved over-the-counter weight loss aid that works by preventing the absorption of dietary fat. It is designed for use in adults with a body mass index (BMI) of 25 or higher, as part of a reduced-calorie, low-fat diet and exercise program. By blocking enzymes that break down fat in the digestive system, Alli helps users manage caloric intake more effectively, supporting sustainable weight management when used as directed under appropriate medical guidance.

Features

• Contains orlistat 60 mg per capsule
• Non-systemic mode of action; works locally in the gastrointestinal tract
• Prevents absorption of approximately 25% of dietary fat
• Gluten-free formulation
• Available without prescription for adult use
• Packaged with detailed usage guide and dietary support materials

Benefits

• Supports clinically meaningful weight loss when combined with lifestyle modifications
• Helps users develop healthier eating habits by reinforcing low-fat dietary choices
• Provides a pharmacological adjunct to diet and exercise for individuals struggling with weight management
• Non-stimulant formula avoids cardiovascular and central nervous system effects associated with other weight loss products
• Encourages long-term weight maintenance through behavioral and dietary awareness
• FDA-approved with demonstrated safety and efficacy profile in multiple clinical trials

Common use

Alli is indicated for weight management in overweight adults (BMI ≥25) as part of a comprehensive weight loss program that includes reduced-calorie nutrition and regular physical activity. It is particularly useful for individuals who have had difficulty losing weight through diet and exercise alone. The medication is intended for medium to long-term use (typically 6 months to 1 year) under periodic medical supervision to monitor progress and adjust management strategies.

Dosage and direction

Take one 60 mg capsule with water immediately before, during, or up to one hour after each main meal containing fat (maximum three capsules daily). If a meal is missed or contains no fat, omit the dose. The medication requires consistent dietary fat intake (not exceeding 30% of total daily calories) to function properly and minimize gastrointestinal effects. Do not exceed recommended dosage. Continue use only if meaningful weight loss (at least 5% of body weight) occurs within 12 weeks.

Precautions

• Not for use by individuals with reduced bile secretion or chronic malabsorption syndromes
• Use with caution in patients with history of hyperoxaluria or calcium oxalate nephrolithiasis
• May reduce absorption of fat-soluble vitamins (A, D, E, K) and beta-carotene; take multivitamin supplement containing these nutrients at bedtime
• Not recommended for use beyond two years without medical reassessment
• Discontinue use if significant weight loss does not occur within 12 weeks of initiation
• Regular monitoring of weight, dietary habits, and potential nutritional deficiencies recommended

Contraindications

• Pregnancy and breastfeeding
• Organ transplant recipients
• Hypersensitivity to orlistat or any component of the formulation
• Chronic malabsorption syndrome
• Cholestasis
• Co-administration with cyclosporine
• Patients taking warfarin or other anticoagulants (requires special monitoring)
• Underweight individuals (BMI <25)
• Children under 18 years of age

Possible side effects

Gastrointestinal symptoms are common, particularly during initial treatment or with high-fat meals:

• Oily spotting
• Flatus with discharge
• Fecal urgency
• Fatty/oily stool
• Oily evacuation
• Increased defecation
• Fecal incontinence
• Abdominal discomfort/pain
• Liquid stools

These effects generally diminish with continued use and dietary fat restriction. Rare cases of severe liver injury have been reported, though causal relationship remains uncertain.

Drug interaction

• Anticoagulants (warfarin): Monitor INR regularly as orlistat may affect vitamin K absorption
• Cyclosporine: Avoid concomitant use; administer at least 2 hours apart
• Levothyroxine: Separate administration by at least 4 hours
• Antiepileptic drugs (e.g., valproate, lamotrigine): Monitor drug levels
• Antiretroviral medications (particularly HIV protease inhibitors): Potential reduced efficacy
• Amiodarone: Possible reduced absorption
• Fat-soluble vitamins: Supplementation required
• Oral contraceptives: Theoretical risk of reduced efficacy; recommend backup method

Missed dose

If a dose is missed, take it with the next fat-containing meal. Do not double the dose to make up for a missed one. If a meal contains no fat, skip the dose entirely. Consistency with meals improves treatment efficacy and reduces gastrointestinal side effects.

Overdose

No serious adverse effects expected from single overdose. Maximum daily dose should not exceed three capsules. Cases of excessive intake may result in severe gastrointestinal effects including steatorrhea, abdominal cramping, and diarrhea. Treatment is symptomatic and supportive. Maintain hydration and consider temporary fat restriction. Medical attention recommended if severe symptoms persist.

Storage

Store at room temperature (20-25°C/68-77°F) in original container with tight closure. Protect from moisture and light. Keep out of reach of children. Do not use after expiration date printed on packaging. Do not transfer capsules to other containers as humidity protection may be compromised.

Disclaimer

This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Alli should be used as part of a comprehensive weight management program under medical supervision, particularly for individuals with pre-existing medical conditions or those taking concomitant medications. Consult healthcare provider before starting any weight loss program, especially if you have history of eating disorders, thyroid disease, diabetes, kidney stones, or liver disease. Regular medical follow-up is recommended during treatment.

Reviews

Clinical studies demonstrate that orlistat 60 mg, when combined with lifestyle modification, produces significantly greater weight loss than placebo alone. In a 16-week study, 57% of patients achieved ≥5% weight loss compared to 31% with placebo. Long-term data shows maintenance of weight loss for up to two years with continued use. Real-world evidence suggests highest success rates occur in motivated individuals who adhere strictly to dietary recommendations and maintain regular physical activity. Most users report adaptation to gastrointestinal effects within several weeks when following low-fat diet guidelines.